DDR1 and endometrial cancer: Besides PARP inhibitors, there are other DDR inhibitors considered emerging targeted agents, which are expected to be effective in immune-checkpoint-inhibitor-resistant tumors and synergy with immunotherapy to improve the survival outcomes of endometrial cancer with poor prognosis.